D1 Capital Partners L.P. Reduces Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

D1 Capital Partners L.P. cut its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 12.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,203,900 shares of the company's stock after selling 302,707 shares during the quarter. D1 Capital Partners L.P. owned 6.66% of Lexeo Therapeutics worth $14,502,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD acquired a new position in Lexeo Therapeutics during the fourth quarter worth $69,000. Altium Capital Management LLC acquired a new position in shares of Lexeo Therapeutics in the fourth quarter valued at $2,665,000. Marshall Wace LLP acquired a new position in Lexeo Therapeutics during the fourth quarter worth $117,000. Jump Financial LLC acquired a new position in Lexeo Therapeutics during the fourth quarter worth $134,000. Finally, Walleye Capital LLC bought a new stake in shares of Lexeo Therapeutics during the fourth quarter worth $407,000. Hedge funds and other institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Trading Down 1.8 %

Shares of Lexeo Therapeutics stock traded down $0.07 on Tuesday, reaching $3.49. 120,137 shares of the company's stock were exchanged, compared to its average volume of 423,096. The company has a market capitalization of $115.69 million, a P/E ratio of -1.10 and a beta of 1.52. The firm's 50-day moving average is $2.97 and its two-hundred day moving average is $5.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics, Inc. has a 52 week low of $1.45 and a 52 week high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.09. Sell-side analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LXEO has been the topic of several recent research reports. Leerink Partners decreased their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a report on Monday, March 24th. Royal Bank of Canada lowered their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. HC Wainwright reaffirmed a "buy" rating and issued a $23.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, April 8th. Finally, Chardan Capital cut their price target on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Tuesday, April 8th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $22.20.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.